Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 1:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 8,388 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Capsule Clear all
Completed Phase 2 Interventional Accepts healthy volunteers

PDD in Type 2 Diabetes w/wo Diastolic Dysfunction

NCT03744975
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diastolic Dysfunction
Interventions
LCZ 696, Placebos
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 28, 2026, 1:20 PM EDT
Recruiting Phase 3 Interventional

Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)

NCT06274801
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Seralutinib, Gereic Dry Powder Inhaler
Drug · Device
Lead sponsor
Gossamer Bio USA, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
33
States / cities
Fresno, California • Los Angeles, California • Sacramento, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 28, 2026, 1:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Maqui Berry Extract and Omega-3 Fatty Acids for Cytokine Reduction

NCT04914312
View directory record Official record
Conditions
Inflammation
Interventions
Maqui berry/omeg-3 fatty acids, Placebos
Dietary Supplement
Lead sponsor
Arizona State University
Other
Eligibility
50 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Oct 28, 2026, 1:20 PM EDT
Completed Phase 2 Interventional Results available

Topiramate to Aid Smoking Cessation in Alcohol Dependent Men

NCT00802412
View directory record Official record
Conditions
Nicotine Dependence, Alcohol Dependence
Interventions
Topiramate, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 70 Years · Male only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Oct 28, 2026, 1:20 PM EDT
Recruiting Phase 2 Interventional

Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN

NCT06797518
View directory record Official record
Conditions
Glomerulonephritis, IGA, Immunoglobulin A Nephropathy
Interventions
Iptacopan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
9
States / cities
Birmingham, Alabama • Los Angeles, California • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 28, 2026, 1:20 PM EDT
Completed Phase 3 Interventional Results available

Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

NCT00936390
View directory record Official record
Conditions
Prostate Cancer
Interventions
bicalutamide, flutamide, LHRH agonist (antagonist) therapy, Dose-Escalated Radiation Therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
1,538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2025
U.S. locations
499
States / cities
Birmingham, Alabama • Fairbanks, Alaska • Peoria, Arizona + 353 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 28, 2026, 1:20 PM EDT
Completed Phase 2 Interventional Results available

N-acetylcysteine (NAC) for Children With Tourette Syndrome

NCT01172288
View directory record Official record
Conditions
Tourettes Syndrome, Tic
Interventions
N-Acetylcysteine (NAC), Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
8 Years to 17 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Oct 28, 2026, 1:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics And Relative Bioavailability Study Of Oxycodone in Healthy Volunteers

NCT01717027
View directory record Official record
Conditions
Healthy
Interventions
Oxycodone
Drug
Lead sponsor
Pain Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 31, 2015 · Synced Oct 28, 2026, 1:20 PM EDT
Recruiting Phase 1 Interventional

Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer

NCT06515470
View directory record Official record
Conditions
Breast Cancer
Interventions
BTX-9341, Fulvestrant
Drug
Lead sponsor
Biotheryx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Rochester, Minnesota • Omaha, Nebraska • Houston, Texas + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2025 · Synced Oct 28, 2026, 1:20 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)

NCT04305041
View directory record Official record
Conditions
Melanoma
Interventions
Pembrolizumab, Quavonlimab, Vibostolimab, Lenvatinib, ATRA
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 120 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
13
States / cities
Los Angeles, California • Santa Monica, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 28, 2026, 1:20 PM EDT
Active, not recruiting Phase 2 Interventional

Study of SPG302 in Adults With Schizophrenia

NCT06442462
View directory record Official record
Conditions
Schizophrenia
Interventions
SPG302, Placebo
Drug
Lead sponsor
Spinogenix
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Garden Grove, California
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 28, 2026, 1:20 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery

NCT03904862
View directory record Official record
Conditions
Medulloblastoma, Childhood, Medulloblastoma Recurrent, Medulloblastoma
Interventions
CX 4945
Drug
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
3 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
12
States / cities
Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 28, 2026, 1:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Epicatechin on Statins for Mitochondrial Dysfunction and Impaired Exercise Capacity

NCT02490527
View directory record Official record
Conditions
Statin Intolerance
Interventions
Pure epicatechin capsules (50mg), Simvastatin (40mg), Placebo
Dietary Supplement · Drug · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
30 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 28, 2026, 1:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Compare Pharmacokinetic(PK) Profiles of XZK vs Lovastatin in Healthy Male Volunteers

NCT02603770
View directory record Official record
Conditions
Lipid Metabolism Disorder
Interventions
XueZhiKang, Lovastatin
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Oct 28, 2026, 1:20 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

An Endometrial Cancer Chemoprevention Study of Metformin

NCT01697566
View directory record Official record
Conditions
Gynecology
Interventions
Metformin, Placebo, Endometrial Biopsy, Lifestyle Intervention, Questionnaires
Drug · Other · Procedure + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
50 Years to 65 Years · Female only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Oct 28, 2026, 1:20 PM EDT
Completed Phase 2 Interventional Results available

The ENRGISE (ENabling Reduction of Low-Grade Inflammation in SEniors) Pilot Study

NCT02676466
View directory record Official record
Conditions
Inflammation
Interventions
Omega-3 fish oil, Losartan, Corn Oil (Fish oil Placebo), Cellulose Based (Losartan Placebo)
Dietary Supplement · Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
70 Years and older
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
Gainesville, Florida • Chicago, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 28, 2026, 1:20 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC

NCT06010329
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Sutetinib Maleate Capsule
Drug
Lead sponsor
Teligene US
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
9
States / cities
Glendale, California • La Jolla, California • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 28, 2026, 1:20 PM EDT
Terminated No phase listed Observational

Pain Study to See if Ultram ER Will Provide Relief to Subjects Whose Pain is Not Well Controlled by Narcotics

NCT00505531
View directory record Official record
Conditions
Chronic Pain
Interventions
Tramadol Extended Release Oral Capsule, Benadryl
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 22, 2020 · Synced Oct 28, 2026, 1:20 PM EDT
Active, not recruiting Phase 1 Interventional

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

NCT05259839
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
Etentamig, Dexamethasone, Lenalidomide, Pomalidomide, Daratumumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2033
U.S. locations
15
States / cities
Little Rock, Arkansas • Miami, Florida • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 28, 2026, 1:20 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Pregabalin in Patients With Radicular Pain

NCT00908375
View directory record Official record
Conditions
Neuropathy; Radicular, Lumbar, Lumbosacral, Failed Back Surgery Syndrome, Spinal Stenosis, Herniated Disc
Interventions
Pregabalin, Sugar Pill
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 64 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 13, 2014 · Synced Oct 28, 2026, 1:20 PM EDT
Terminated Not applicable Interventional

Vitamin E Treatment for Long-Chain 3-Hydroxyacyl Coenzyme A (CoA) Dehydrogenase (LCHAD) Associated Neuropathy

NCT00840112
View directory record Official record
Conditions
Peripheral Neuropathy, Mitochondrial Trifunctional Protein Deficiency
Interventions
Vitamin E supplement
Dietary Supplement
Lead sponsor
Oregon Health and Science University
Other
Eligibility
7 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 21, 2015 · Synced Oct 28, 2026, 1:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nitrate and Vitamin C on Vascular Health Oxidative Stress

NCT04283630
View directory record Official record
Conditions
Endothelial Dysfunction
Interventions
Dietary nitrate in the form of beetroot juice for all participnats, Nature Made vitamin c 1000 mg, Placebo
Dietary Supplement
Lead sponsor
David Travis Thomas
Other
Eligibility
50 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Oct 28, 2026, 1:20 PM EDT
Completed Phase 3 Interventional Results available

Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy

NCT02791230
View directory record Official record
Conditions
Transthyretin (TTR) Amyloid Cardiomyopathy
Interventions
Tafamidis
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,733 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
41
States / cities
Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 28, 2026, 1:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Cognitive Effects of Oral Oxybutynin and Oxybutynin Chloride Topical Gel in Older Volunteers

NCT00752141
View directory record Official record
Conditions
Healthy Volunteers
Interventions
oxybutynin chloride immediate-release, oxybutynin chloride topical gel, placebo
Drug · Other
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
60 Years to 79 Years
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
6
States / cities
Tucson, Arizona • National City, California • Maitland, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2011 · Synced Oct 28, 2026, 1:20 PM EDT